We have located links that may give you full text access.
Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate.
American Journal of Health-system Pharmacy : AJHP 2017 September 2
PURPOSE: The change in turnaround time of 4-factor prothrombin complex concentrate (PCC) when managed by the pharmacy department compared to blood bank management was evaluated.
METHODS: A retrospective analysis evaluated blood bank versus pharmacy management of PCC. Blood bank management was evaluated from November 2014 to November 2015, and pharmacy management was evaluated from December 2015 to July 2016. Chart review was performed on all patients who received PCC during these study periods. The primary outcome was the difference in median time from order entry to administration between management groups. Comparisons were made for the appropriateness of clinical use, length of stay, and discharge status. The primary outcome was analyzed using a Mann-Whitney U test. Secondary outcomes were analyzed using the chi-square test or Fisher's exact test. Descriptive statistics were utilized to analyze secondary outcomes.
RESULTS: Forty-three patients received PCC in the blood bank group, and 22 patients received PCC in the pharmacy group. Median turnaround time of PCC was lower in the pharmacy group (43 minutes; interquartile range [IQR], 32-65 minutes) compared to the blood bank group (62 minutes; IQR; 39-110 minutes; p = 0.032). PCC use was clinically appropriate for 55% of patients (n = 12) in the pharmacy group compared with 37% of patients (n = 16) in the blood bank group (p = 0.182). There were no significant differences between the blood bank and pharmacy groups with regard to hospital length of stay or in-hospital mortality.
CONCLUSION: Conversion of PCC management from the blood bank to the pharmacy was associated with a significant decrease in time to PCC administration.
METHODS: A retrospective analysis evaluated blood bank versus pharmacy management of PCC. Blood bank management was evaluated from November 2014 to November 2015, and pharmacy management was evaluated from December 2015 to July 2016. Chart review was performed on all patients who received PCC during these study periods. The primary outcome was the difference in median time from order entry to administration between management groups. Comparisons were made for the appropriateness of clinical use, length of stay, and discharge status. The primary outcome was analyzed using a Mann-Whitney U test. Secondary outcomes were analyzed using the chi-square test or Fisher's exact test. Descriptive statistics were utilized to analyze secondary outcomes.
RESULTS: Forty-three patients received PCC in the blood bank group, and 22 patients received PCC in the pharmacy group. Median turnaround time of PCC was lower in the pharmacy group (43 minutes; interquartile range [IQR], 32-65 minutes) compared to the blood bank group (62 minutes; IQR; 39-110 minutes; p = 0.032). PCC use was clinically appropriate for 55% of patients (n = 12) in the pharmacy group compared with 37% of patients (n = 16) in the blood bank group (p = 0.182). There were no significant differences between the blood bank and pharmacy groups with regard to hospital length of stay or in-hospital mortality.
CONCLUSION: Conversion of PCC management from the blood bank to the pharmacy was associated with a significant decrease in time to PCC administration.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app